Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 34.22
+0.58 (1.72%)
Jan 23, 2026, 3:00 PM CST
Kexing Biopharm Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Net Income | 125.57 | 31.48 | -190.29 | -90.3 | 96.46 | 139.14 | Upgrade |
Depreciation & Amortization | 99.03 | 99.03 | 88.26 | 71.04 | 49.88 | 29.14 | Upgrade |
Other Amortization | 7.69 | 7.69 | 11.01 | 9.97 | 6.75 | 4.55 | Upgrade |
Loss (Gain) From Sale of Assets | -0.08 | -0.08 | -0.28 | -1.46 | 0.47 | 0.05 | Upgrade |
Asset Writedown & Restructuring Costs | 0.17 | 0.17 | 1.6 | 0.42 | 2.94 | 1.41 | Upgrade |
Loss (Gain) From Sale of Investments | 19.65 | 19.65 | -7.17 | 1.52 | -56.65 | - | Upgrade |
Provision & Write-off of Bad Debts | 1.4 | 1.4 | -3.13 | 0.17 | -1.77 | 1.92 | Upgrade |
Other Operating Activities | -111.81 | 42.81 | 35.57 | 22.97 | 10.99 | 20.1 | Upgrade |
Change in Accounts Receivable | -228.07 | -228.07 | -70.17 | -85.91 | -66.53 | -123.21 | Upgrade |
Change in Inventory | 45.89 | 45.89 | -14.87 | -35.26 | -59.28 | 26.94 | Upgrade |
Change in Accounts Payable | 69.46 | 69.46 | 124.93 | 60.42 | 111.97 | 5.32 | Upgrade |
Change in Other Net Operating Assets | 4.37 | 4.37 | 7.72 | 7.85 | - | - | Upgrade |
Operating Cash Flow | 46.14 | 106.67 | -87.14 | -85.89 | 94.01 | 105.93 | Upgrade |
Operating Cash Flow Growth | 13.57% | - | - | - | -11.25% | 1916.17% | Upgrade |
Capital Expenditures | -77.39 | -93.99 | -191.2 | -399.17 | -371.98 | -188.97 | Upgrade |
Sale of Property, Plant & Equipment | 1.17 | 0.04 | - | 1.78 | 64.47 | 0.51 | Upgrade |
Investment in Securities | 22.53 | -8.37 | 12.05 | - | -200 | - | Upgrade |
Other Investing Activities | 16.2 | -1.8 | 22.9 | 15.94 | 15.01 | -12.1 | Upgrade |
Investing Cash Flow | -25.07 | -104.13 | -156.25 | -381.45 | -492.5 | -200.55 | Upgrade |
Long-Term Debt Issued | - | 627.66 | 420.63 | 1,016 | 505.52 | 338.37 | Upgrade |
Long-Term Debt Repaid | - | -569.77 | -371.69 | -591.08 | -284.65 | -291.99 | Upgrade |
Net Debt Issued (Repaid) | 241.24 | 57.88 | 48.93 | 424.72 | 220.88 | 46.38 | Upgrade |
Issuance of Common Stock | 26.22 | 6.96 | 7.82 | - | - | 1,015 | Upgrade |
Repurchase of Common Stock | -31.13 | -31.13 | - | - | - | - | Upgrade |
Common Dividends Paid | -56.86 | -43.63 | -45.41 | -53.63 | -28.39 | -10.87 | Upgrade |
Other Financing Activities | -15.51 | -1 | 4.91 | - | -5.55 | -14.93 | Upgrade |
Financing Cash Flow | 163.96 | -10.91 | 16.25 | 371.1 | 186.94 | 1,036 | Upgrade |
Foreign Exchange Rate Adjustments | 1.45 | 1.39 | 3.09 | 5.43 | -2.07 | -3.32 | Upgrade |
Net Cash Flow | 186.47 | -6.98 | -224.04 | -90.81 | -213.61 | 938.03 | Upgrade |
Free Cash Flow | -31.24 | 12.68 | -278.34 | -485.06 | -277.97 | -83.04 | Upgrade |
Free Cash Flow Margin | -2.06% | 0.90% | -22.11% | -36.86% | -21.63% | -6.80% | Upgrade |
Free Cash Flow Per Share | -0.15 | 0.06 | -1.40 | -2.42 | -1.41 | -0.56 | Upgrade |
Cash Income Tax Paid | 52.14 | 60.51 | 49.54 | 35.35 | 41.63 | 83.31 | Upgrade |
Levered Free Cash Flow | -140.67 | -89.72 | -244.19 | -461.11 | -246.11 | -87.27 | Upgrade |
Unlevered Free Cash Flow | -113.6 | -61.69 | -218.74 | -443.17 | -241.1 | -80.81 | Upgrade |
Change in Working Capital | -95.48 | -95.48 | -22.7 | -100.22 | -15.07 | -90.38 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.